One of the current challenges in the evaluation of novel agents for the treatment of advanced prostate cancer is the identification of a surrogate end point for overall survival (OS). Prostatespecific antigen (PSA) levels have been used as a screening tool and a biomarker of response to both hormonal and cytotoxic agents. However, PSA levels do not seem to be a suitable surrogate end point for OS in trials of targeted agents for castrate-resistant prostate cancer (CRPC). These findings suggest the need for adopting measures of efficacy that more accurately reflect the mechanisms of action of these agents in phase II trials, in order to realize improvements in OS in the phase III setting. The Prostate Cancer Clinical Trials Working Group (PCWG2) have recently made recommendations for the design of future trials and advised that PSA levels should not be the sole criterion on which to base clinical decisions. Here, we appraise the end points that have been used in phase II and III trials in patients with CRPC, and highlight the need for the adoption of the PCWG2 guidelines, the recommendations of which include radiographic imaging, in addition to bone scintigraphy, and symptomatic or radiographic disease progression criteria.
Introduction
The main aim of assessing outcomes in clinical trials is to provide objective, quantifiable measures that will reflect any clinical benefit obtained by patients. One of the major current challenges to evaluate novel agents in advanced prostate cancer is the lack of a readily identifiable surrogate end point for overall survival (OS). There are several reasons for this: changes in prostate-specific antigen (PSA) may be dissociated from recognized clinical outcomes such as OS or pain palliation; changes in radionuclide bone scans are difficult to quantify objectively; and Response Evaluation Criteria in Solid Tumours (RECIST) are difficult to apply when monitoring the development of bone metastases in prostate cancer.
Broadening knowledge of the pathways involved in prostate cancer progression has led to the development of novel therapies, many of which have the effect of slowing tumour growth rather than killing tumour cells, and which therefore reduce prostate cancer-specific morbidity and mortality without necessarily producing objective tumour shrinkage. To ensure the effective development of these agents, the adoption of measures of efficacy in phase II trials in castrate-resistant prostate cancer (CRPC), which more accurately reflects their mechanisms of action, will be required, to realize improvements in OS in the phase III setting.
Appraisal of end points in phase II and III trials in castrate-resistant prostate cancer
Prostate-specific antigen PSA levels have an important function in the diagnosis and management of prostate cancer, and PSA has been variously described as a prognostic (or predictive) factor, biomarker and surrogate end point. Its widespread use as a screening tool has led to its application in individual patients, as a prognostic indicator of disease evolution, and as a biomarker of response to both hormonal and cytotoxic agents in advanced disease. However, established prognostic factors are not always valid surrogate end points. A surrogate end point must be associated with a clinical outcome, and fully capture the net effect of any treatment on that outcome. 1 To confirm surrogacy, one must therefore show a strong correlation between the treatment's relative effect on the surrogate and on the true end point in patients treated with a new versus standard intervention. 2 The PSA Working Group (PCWG1) 3 published criteria for a PSA partial response, which were strongly prognostic in studies of cytotoxic agents. However, despite extensive investigation, PSA has not been established as a surrogate end point in CRPC. There are several biological and medical reasons why PSA may be unsuitable as a surrogate end point in clinical trials for the treatment of advanced prostate cancer. Overall, only part of the treatment effect is reflected in changes in the biomarker, which could lead to over-or underestimation of efficacy for a drug. 4 Indeed, declining PSA values may not indicate that an intervention is working, and rising values may not indicate that it is failing. 5 The following examples highlight why the use of pretreatment changes in PSA as a prognostic indicator must be distinguished from the use of post-treatment changes in PSA as an outcome measure to assess the clinical benefit to a patient or the effect of an intervention on the disease.
Evaluation of cytotoxic agents. A pivotal assessment of PSA as a surrogate for OS was performed as part of the Southwest Oncology Group (SWOG) 99-16 study, 6 in which patients with androgen-independent prostate cancer were assigned treatment with docetaxel/estramustine or mitoxantrone/prednisone. The group receiving docetaxel gained a 2-3 month OS benefit. After the first 3 months' therapy, a PSA decline of at least 30% was associated with a greater than 50% decrease in the risk of death, compared with a PSA decline of o30% (hazard ratio ¼ 0.43, Po0.001), satisfying criteria for its use as a surrogate end point.
However, the association was less clear in the phase III TAX327 study comparing docetaxel (weekly or every 3 weeks) plus daily prednisone versus mitoxantrone plus prednisone in men with metastatic hormone-resistant prostate cancer (HRPC), in which PSA was a secondary end point to OS. The response rate (X50% reduction in serum PSA) was significantly higher in both docetaxel groups compared with the mitoxantrone group (Po0.001). 7 However, there was no difference in PSA response rate between the two docetaxel regimens, despite a significantly higher survival rate (P ¼ 0.009) in the group given docetaxel every 3 weeks but not in the group given weekly docetaxel (P ¼ 0.36). PSA response would therefore not be a reliable surrogate end point for OS when comparing a weekly schedule of docetaxel with mitoxantrone.
Evaluation of molecular-targeted agents. PSA progression has also been investigated as part of the clinical evaluation of several molecular-targeted agents, and as with cytotoxic agents, the results here also indicated that PSA progression might not be a suitable surrogate end point for OS.
In the phase II Androgen-independent prostate cancer study of calcitriol enhancing taxotere (ASCENT) study of high-dose calcitriol (DN-101) plus docetaxel versus placebo plus docetaxel in patients with progressive metastatic HRPC, PSA responses were recorded in 49% of placebo-treated patients and 58% of DN-101-treated patients (P ¼ 0.16) within 6 months of starting treatment. However, OS in the DN-101-treated group was improved significantly over the placebo group (P ¼ 0.04). 8 Similar findings were reported in the development of the immunotherapeutic agent APC8015 (Provenge). 9 In a double-blind phase II trial evaluating zibotentan (ZD4054), an endothelin A (ET A ) receptor-specific antagonist, pain-free or mildly symptomatic HRPC patients with bone metastases received once-daily zibotentan (15 or 10 mg/day) or placebo. 10 At the second analysis, median OS was 23.5 months (P ¼ 0.052) and 24.5 months (P ¼ 0.008) for the 15 and 10 mg/day doses, compared with 17.3 months for placebo. However, no significant differences in time to PSA progression were observed between the zibotentan treatment groups and placebo.
Atrasentan is a selective ET A receptor antagonist with evidence of supplementary affinity for the endothelin B receptor, for which two randomized, placebo-controlled phase III trials have recently been reported in the HRPC setting. 11, 12 In patients with metastatic disease, atrasentan did not affect the time to disease progression relative to placebo (P ¼ 0.136) despite evidence of biologic effects on PSA and bone alkaline phosphatase as markers of disease burden. 11 These biologic effects were also observed in patients with nonmetastatic HRPC. 12 In the latter trial, although the primary end point of time to progression was 93 days longer in the atrasentan arm than the placebo arm, neither this difference (P ¼ 0.288), nor the survival difference of 74 days (P ¼ 0.219) was significant.
Interesting geographic differences in clinical practice were noted in this study: the median time to progression was 590 days in patients treated in the US and 847 days in non-US patients. A suggested reason for this was premature discontinuation of the drug: US patients were twice as likely to discontinue drug early compared with non-US patients (40.8 versus 21.9%; Po0.001). Although the primary reason for discontinuation was adverse events, the median increase in PSA at the time of discontinuation in the atrasentan arm was 12.5 ng ml À1 in the US patients and 20.3 ng ml À1 in the non-US patients, suggesting the rising PSA level was a trigger to stop the drug. Although an increase in PSA was not considered to be disease progression according to the protocol, the discontinuation rate based on PSA progression was four times higher in US patients in the study (5.3 versus 1.1%). The question of how to maintain patients on effective therapy, despite rising PSA, was identified as the most challenging issue highlighted by this study. 13 The Prostate Cancer Clinical Trials Working Group (PCWG2) has recently addressed this issue and made recommendations for the design of future clinical trials with the aim of ensuring that a drug is not discontinued prematurely because of the use of inappropriate outcome measures.
14 Recognizing that absence of early changes in PSA levels are not sufficient to justify discontinuation of treatment, the PCWG2 advises against their use as the sole criterion on which to base clinical decisions. The Group also cautioned against the use of post-therapy changes in PSA doubling times, given the modest association between PSA declines and outcomes. 15 A robust PSAbased surrogate for clinical benefit is yet to be identified.
The PCWG2 also highlighted that drug evaluation pathways for cytotoxic and non-cytotoxic agents need to be developed separately, based on the different effects these agents have on PSA levels, which may occur independently of an effect on tumour cell growth or OS. The PCWG2 recommends that trial outcomes be reported separately and that patients be kept on a trial therapy until radiographic or symptomatic progression is Measuring therapeutic efficacy in CRPC PF Mulders and JA Schalken documented rather than solely on the basis of PSA level changes. The potential benefit of this approach was shown in an exploratory analysis of data from a phase II trial of docetaxel, bevacizumab and thalidomide in patients with metastatic CRPC. The use of clinical (radiographic or symptomatic) progression safely extended treatment after PSA progression, and was associated with an improved survival compared with discontinuation solely on the basis of PSA progression. 16 Also, in keeping with this evolving concept, in a recent two-stage phase II study with sorafenib, a discordance between PSA increases and improvements in bone scans was seen in Part I of the study. The original protocol indicated that no further patients would be enrolled if seven or fewer patients were found to be progression-free at the end of the Part I. However, the observed discrepancy between PSA and bone scans meant that the protocol was amended to remove PSA-defined progression as a progression criterion, and the study continued into Part II. 17 
Progression-free survival and time to progression
In a clinical trial, progression-free survival (PFS) is often seen as the best confirmation that a drug either has not worked or is no longer effective. Given its relative proximity to OS in the follow-up period of a trial, it can be a more informative intermediate end point, having a strong association with survival, while being available earlier. It is also, unlike OS, not influenced by second-line treatment choices. As bone is the primary site of metastases in HRPC, it is more straightforward to measure progression than response in prostate cancer trials. This has led to an increasing focus on PFS as an end point in phase II trials. However, PFS is difficult to define and measure in advanced prostate cancer, and is influenced by the timing of scheduled reassessments. The concept of progression also has many potential manifestations, each of varying importance: a modest increase in the size of pelvic lymph nodes that, though asymptomatic, are radiographically detectable; the appearance of asymptomatic lesions on a radionuclide scan; the development of significant clinical sequelae, such as ureteral obstruction or painful bone lesions, or an increase in PSA levels. 18 Given these limitations, it is perhaps unsurprising that so little is known about the correlation between PFS and measures of clinical benefit, and few studies have explored the PFS-OS association, partly because the methodology is non-standard, as both PFS and OS are time to event end points. As a result, any measures of association must account for censoring in PFS and OS. Variability is increased as survival times can be assessed on a continuous daily basis, whereas PFS is assessed at intervals; if the assessment intervals are too long, a measure of PFS may become meaningless. 19 The variety of assessment schedules used across studies mean that PFS is also vulnerable to inter-study design variability. This was highlighted in a review of phase II CRPC clinical trials, which showed a high variability, despite published guidelines designed to standardize confirmation of disease progression. 19 In a retrospective analysis exploring the association between radiographic (as well as PSA) PFS and OS in patients with CRPC treated with microtubule-targeted chemotherapy, 20 overall concordance was moderate for both progression measures: 0.4 for radiographic PFS and 0.33 for PSA PFS. The association between radiographic PFS and OS was weakest early in follow-up, whereas the PSA association was weakest when the PFS-related event occurred more than 6 months after treatment started. The authors concluded that current measures of PFS in CRPC were not strong surrogates for OS. Factors reducing the association included interval censoring of progression data and early discontinuation of therapy in the follow-up because of imaging changes that may not have represented a real failure of the treatment. This was also the case in the atrasentan trials, 11, 12 where a protocol-specified definition of progression resulted in the removal from the study of many patients who had declining PSA values and stable or improving symptoms.
A variety of definitions of progression have been evaluated in the TAX327 study for post-progression survival and the benefit associated with continuing or stopping chemotherapy. 21 The authors showed that the more criteria that were met for progression, the lower the rate of post-progression survival. A survival advantage to continuing chemotherapy was suggested for those men who had pain progression only. These data highlight the potential usefulness of composite PFS definitions, and a number of recent trials have used composite end points for PFS, which have included tumour progression, skeletal events and symptomatic progression (i.e. pain), but not PSA changes. For example, in the phase II zibotentan trial, 10 PFS was the primary end point, defined as a composite of clinical or symptomatic progression, skeletal events or death. Although in this trial PFS was not statistically different from placebo, zibotentan did significantly prolong OS. Conversely, in the randomized multicentre double-blind phase III SPARC study comparing the novel platinum compound satraplatin and prednisone with prednisone and placebo, although exhibiting a significant reduction in risk of PFS and decreased pain progression, satraplatin failed to significantly impact OS. 22 
Radiologic response
The relatively low association between PFS and OS suggests that physiological processes using pathways that do not effect changes in bone scan or PSA are involved. 23 Methods to assess progression, including the frequency and interpretation of imaging procedures, and the relationship between asymptomatic radiographic events and clinically meaningful outcomes, must therefore be refined. The clinical issues raised by these observations were highlighted in a study by Scher et al. 24 Applying RECIST criteria to men with CRPC, less than half of the patients had measurable lesions greater than 2 cm in size, and the lesions were mainly lymph nodes, which are not always present in advanced disease. There are also no criteria in RECIST for patients with flare phenomena, in which healing bone lesions may appear as either existing lesions becoming worse or as totally new lesions. The PCWG2 guidelines should provide for a more accurate confirmation of progression of bone metastases that are imaged using bone scintigraphy, as two unequivocally new lesions are now required, and additional lesions must be observed on a Measuring therapeutic efficacy in CRPC PF Mulders and JA Schalken subsequent scan before disease progression can be confirmed. Although this should help avoid the situation in which therapy that is otherwise beneficial is stopped prematurely, 14 techniques such as magnetic resonance imaging (MRI) of the axial skeleton, positron emission tomography (PET) and single photon emission computed tomography (SPECT) may be more sensitive in detecting and monitoring bone metastases. In a recent study, MRI of the axial skeleton was shown to be superior to skeletal scintigraphy with regard to diagnosis and follow-up of bone metastases in men with CRPC. 25 In an analysis of planar bone scintigraphy, SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT in men with high-risk prostate cancer, the superiority of 18F-fluoride PET/CT over SPECT over bone scintigraphy was shown for both sensitivity and specificity to detect bone metastases. 26 These data suggest that whole-body MRI or 18F-flouride PET/CT may in time become the imaging modality of choice for detection and assessment of osseous metastases in prostate cancer. 27 
Pain and quality of life improvements
Pain-related markers and other cancer symptomatology can serve as useful indicators of clinical benefit in CRPC patients. In two studies comparing mitoxantrone and prednisone with prednisone alone, improved pain control and duration, and increased quality of life were shown in the mitoxantrone-treated patients, 28 data that underpinned the approval of mitoxantrone in CRPC. On the basis of favourable data on pain reduction and analgesia use in a recent phase II trial of the clusterin inhibitor OGX-011, the food and drug administration (FDA) has agreed in principle to the use of durable pain palliation as a primary end point in one of its phase III trials in combination with docetaxel.
Patient-reported outcomes are being more frequently used as secondary end points in clinical trials. Only a modest improvement in OS was observed in the TAX327 trial, 7 but concomitant improvements in pain and quality of life have helped achieve the widespread adoption of docetaxel. However, current standards for analysing quality of life and symptom control are vague, and quality of life outcomes are problematic, given their subjectivity and inherent bias.
29,30

Skeletal-related events
With the development of agents targeting specific aspects of disease progression, it is sometimes possible to use an end point that is directly related to the mechanism of action of a particular drug. This was the case with the approval of the bisphosphonate zoledronic acid for the prevention of skeletal-related events, even though the drug did not produce an OS advantage. In a multicentre, randomized controlled trial in patients with prostate cancer and osteoblastic bone lesions, 31 the drug significantly decreased the incidence of bone-related complications, increased the time to first skeletal event and decreased bone pain compared with placebo. This end point therefore represents an alternative route to approval for agents that affect bone health rather than the tumour itself.
Overall survival
Given the limitations associated with PSA declines, tumour responses and improvements in pain, OS remains the 'gold standard' for the evaluation of clinical benefit in CRPC trials. Although this is understandable, it does result in potential delays to the introduction of new therapies, particularly in which survival data are confounded by second-and third-line therapies. In the TAX327 study, OS was the primary end point, and secondary end points included quality of life, pain and PSA levels. 7 The 3-weekly regimen was associated with significant improvements in all of these parameters. However, other currently ongoing phase III trials with a docetaxel-prednisone comparator arm all have an OS primary end point. In the absence of an unambiguous surrogate for clinical benefit, and given the difficulty inherent in validating surrogate end points, it seems unlikely that a novel surrogate will replace OS in the near future.
Novel biomarkers
New biomarkers of disease response in CRPC, if used additionally to PSA, may identify other functional pathways for the disease, and could (like PSA) be monitored serially and frequently in patients to show trends over time. Circulating tumour cells have been detected at high frequency in CRPC and are prognostic for clinical outcomes. 32, 33 In a recent study in CRPC patients receiving cytotoxic chemotherapy, circulating tumour cell levels were measured to monitor treatment response and predict outcome, and unfavourable pretreatment circulating tumour cells were shown to be associated with decreased OS. 34 To further explore the potential link to survival, circulating tumour cells have been incorporated as an exploratory end point in trials of the CYP17 enzyme inhibitor abiraterone acetate. 35 A number of other biomarkers are currently being investigated in efforts to more accurately predict clinical response. PCA3 (DD3) is a primarily urine-based biomarker, and a PCA3 diagnostic test has recently been standardized for whole urine. 36 Levels of sarcosine, a product of the methylation of the amino acid glycine, can also be detected non-invasively in urine, and have been shown to be elevated during metastasis. 37 Human kallikrein 2 (hK2) is a serum protease very similar to PSA, and there is evidence that serum total hK2 levels may better reflect the presence of bone metastases than PSA. 38 Other possible alternatives to PSA, identified in large-scale gene expression analyses include prostatespecific membrane antigen, prostate mucin antigen and PTI-1. 39 The first consistent chromosomal rearrangement in prostate cancer was characterized in a study of 29 prostate cancer patients, in which fusion of the androgen-responsive promoter elements of the TMPRSS2 gene to ERG or ETV1, transcription factors from the ETS family, was observed in 7.9% of the patients. 40 The presence of the fusion gene in prostate cancer biopsy specimens has subsequently been confirmed by other workers, although in a recent study 41 of multifocal prostate cancer from radical prostatectomy specimens, fusion was observed only sporadically, suggesting they may occur at a later stage of the disease.
Although a number of the above markers have robust performance characteristics, no one approach is ideal, Measuring therapeutic efficacy in CRPC PF Mulders and JA Schalken and it may be that greater predictive utility can be attained by combining data from several biomarkers.
Conclusion
In phase II trials, selection of appropriate intermediate end points to measure the efficacy of novel agents remains problematic, although the use of a more refined, robust PFS end point is to be welcomed. The continuing need to measure OS as a primary end point in phase III trials, and the lack of informative intermediate end points that reflect accurately whether a treatment is efficacious, have hindered the availability of new therapeutic options in CRPC. Hence, the inclusion of new generation biomarkers in correlative side studies to phases II and III trials is strongly recommended.
Having the ability to use a surrogate end point, which could be measured earlier and more conveniently, and still adequately reflect the clinical benefit of a treatment on the true end point, would accelerate the drug development process. Interestingly, in a proposed phase III trial of abiraterone plus prednisone in patients with metastatic CRPC, although OS and PFS are co-primary end points, both the FDA and EMEA have agreed to allow PFS data from the trial to form the basis of an accelerated or conditional approval.
The recently published PCWG2 guidelines address the issue of verifying disease progression and achieving uniformity in disease assessments. Its recommendations include radiographic imaging at baseline for soft tissue disease, in addition to bone scintigraphy; discarding early tumour assessments and spacing assessments by at least 12 weeks; and advocating symptomatic or radiographic disease progression criteria, rather than biochemical. However, the guidelines need to be adopted consistently for them to be effective.
In conclusion, the primary purpose of phase III studies is to confirm patient benefit; with currently available measures, this requires OS, quality of life and delay in skeletal events and other significant complications of prostate cancer.
